So on his own he crafted a human version of the antibody, otelixizumab, and cofounded Tolerx in 2000 to commercialize it and other drugs.
FORBES: Magazine Article
2.
Privately held biotech firm Tolerx, allied with GlaxoSmithkline, aims to begin, by summer, a final-stage trial of its anti-CD3 drug, otelixizumab, in 250 newly diagnosed adults.